* histologically or cytologically confirmed prostate cancer, and metastases detected on bone scanning, contrast-enhanced computed tomography (CT), or magnetic resonance imaging (MRI).
* be candidates for androgen-deprivation therapy with/without docetaxel.
Patients for whom the decision to initiate treatment with Darolutamide as a first time was made as per investigator's routine treatment practice
Written informed consent from subject or legal representative; assent from subject when appropriate
You may not be if
Patients participating in an investigational program with interventions outside of routine clinical practice
Participants with contraindication according to the locally approved prescribing information
Clareo Health | An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
